CN111432828A - 用以调节免疫耐受的多功能抗体-配体捕获剂 - Google Patents

用以调节免疫耐受的多功能抗体-配体捕获剂 Download PDF

Info

Publication number
CN111432828A
CN111432828A CN201880049751.9A CN201880049751A CN111432828A CN 111432828 A CN111432828 A CN 111432828A CN 201880049751 A CN201880049751 A CN 201880049751A CN 111432828 A CN111432828 A CN 111432828A
Authority
CN
China
Prior art keywords
receptor
ligand
molecule
seq
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880049751.9A
Other languages
English (en)
Chinese (zh)
Inventor
阿图尔·贝迪
拉贾尼·拉维拉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Johns Hopkins University
Original Assignee
Johns Hopkins University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johns Hopkins University filed Critical Johns Hopkins University
Publication of CN111432828A publication Critical patent/CN111432828A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
CN201880049751.9A 2017-05-26 2018-05-25 用以调节免疫耐受的多功能抗体-配体捕获剂 Pending CN111432828A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762511911P 2017-05-26 2017-05-26
US62/511,911 2017-05-26
US201762592341P 2017-11-29 2017-11-29
US62/592,341 2017-11-29
PCT/US2018/034755 WO2018218215A1 (en) 2017-05-26 2018-05-25 Multifunctional antibody-ligand traps to modulate immune tolerance

Publications (1)

Publication Number Publication Date
CN111432828A true CN111432828A (zh) 2020-07-17

Family

ID=64396014

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880049751.9A Pending CN111432828A (zh) 2017-05-26 2018-05-25 用以调节免疫耐受的多功能抗体-配体捕获剂

Country Status (7)

Country Link
US (3) US20200140547A1 (cg-RX-API-DMAC7.html)
EP (2) EP3630148A4 (cg-RX-API-DMAC7.html)
JP (1) JP2020521759A (cg-RX-API-DMAC7.html)
CN (1) CN111432828A (cg-RX-API-DMAC7.html)
CA (1) CA3064869A1 (cg-RX-API-DMAC7.html)
IL (2) IL311124A (cg-RX-API-DMAC7.html)
WO (1) WO2018218215A1 (cg-RX-API-DMAC7.html)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113698493A (zh) * 2021-08-09 2021-11-26 北京东方百泰生物科技股份有限公司 一种针对VEGF和TGF-β的双功能蛋白及其应用
WO2022111576A1 (en) * 2020-11-27 2022-06-02 Elpiscience (Suzhou) Biopharma, Ltd. Novel conjugate molecules targeting cd39 and tgfβeta
WO2022111476A1 (zh) * 2020-11-24 2022-06-02 普米斯生物技术(珠海)有限公司 抗PD-L1-抗VEGF-抗TGF-β多特异性抗体、其药物组合物及用途
CN116554300A (zh) * 2023-04-27 2023-08-08 湖北医药学院 一种能与艰难拟梭菌毒素TcdB相互作用的多肽及其应用
WO2024046394A1 (zh) * 2022-08-30 2024-03-07 北京卡替医疗技术有限公司 增强受体、表达增强受体的免疫细胞及其用途
WO2026119062A1 (zh) * 2024-12-04 2026-06-11 科辉智药(深圳)新药研究中心有限公司 一种抗pd-l1和hhla2双特异性抗体及其制备方法和应用

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2828739T3 (es) 2006-04-07 2021-05-27 Aerpio Pharmaceuticals Inc Anticuerpos que se unen a la proteína tirosina fosfatasa beta humana (HPTP-beta) y sus usos
MX363351B (es) 2011-10-13 2019-03-20 Aerpio Therapeutics Inc Un agente de unión a hptp?-ecd para usarse en el tratamiento de síndrome de fuga vascular.
WO2015200905A2 (en) 2014-06-28 2015-12-30 Oligasis, Llc Dual pdgf/vegf antagonists
AU2016286108B2 (en) 2015-06-30 2021-03-11 Pfizer Inc. BTLA fusion protein agonists and uses thereof
IL290457B2 (en) 2015-12-30 2025-02-01 Kodiak Sciences Inc Antibodies and their conjugates
BR112019000071A2 (pt) 2016-07-07 2019-07-02 Bolt Biotherapeutics Inc conjugados adjuvantes de anticorpo
WO2018222718A1 (en) 2017-05-30 2018-12-06 Bristol-Myers Squibb Company Treatment of lag-3 positive tumors
JP7301002B2 (ja) 2017-05-30 2023-06-30 ブリストル-マイヤーズ スクイブ カンパニー 抗lag-3抗体または抗lag-3抗体および抗pd-1もしくは抗pd-l1抗体を含む組成物
CA3092588A1 (en) 2018-03-02 2019-09-06 Kodiak Sciences Inc. Il-6 antibodies and fusion constructs and conjugates thereof
EP3856245A4 (en) 2018-09-24 2022-10-26 EyePoint Pharmaceuticals, Inc. MULTISPECIFIC ANTIBODIES AGAINST HPTP - BETA (VE-PTP) AND VEGF
CN113518823B (zh) * 2019-01-07 2025-05-02 托马斯杰斐逊大学 多功能的融合蛋白及其用途
EP3937984A1 (en) 2019-03-15 2022-01-19 Bolt Biotherapeutics, Inc. Immunoconjugates targeting her2
EP3972690A4 (en) * 2019-05-23 2023-07-05 Janssen Biotech, Inc. METHOD OF TREATMENT OF INFLAMMATORY BOWEL DISEASE USING COMBINATION THERAPY OF ANTIBODIES TO IL-23 AND TNF-ALPHA
KR102815892B1 (ko) * 2019-06-10 2025-06-04 샨동 보안 바이오테크놀로지 컴퍼니, 리미티드 PDL1 및 TGFβ에 대한 2기능성 융합 단백질 및 이의 용도
WO2020252421A2 (en) * 2019-06-14 2020-12-17 Cugene, Inc. Novel interleukin-2 variants and bifunctional fusion molecules thereof
US20220235131A1 (en) * 2019-06-17 2022-07-28 The Board Of Trustees Of The Leland Stanford Junior University Methods of treating infections by blocking pathogen mimics of cd47
WO2021007428A2 (en) * 2019-07-09 2021-01-14 The Johns Hopkins University Molecules, compositions and methods for treatment of cancer
CN110627905B (zh) * 2019-09-18 2021-04-27 中国医学科学院肿瘤医院 靶向vegf与egfr的双功能融合蛋白及其应用
WO2021055994A1 (en) * 2019-09-22 2021-03-25 Bristol-Myers Squibb Company Quantitative spatial profiling for lag-3 antagonist therapy
CN112574314A (zh) * 2019-09-30 2021-03-30 和铂医药(苏州)有限公司 一种融合蛋白及其应用
CA3157509A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
EP4054723A1 (en) * 2019-11-08 2022-09-14 Bristol-Myers Squibb Company Lag-3 antagonist therapy for melanoma
CA3158047A1 (en) * 2019-12-11 2021-06-17 Yunying CHEN Bi-functional antibody against pd-l1 and tgf?
WO2021123432A1 (en) * 2019-12-20 2021-06-24 Ares Trading S.A. Igg:tgfbetarii fusion protein composition
US11045546B1 (en) 2020-03-30 2021-06-29 Cytodyn Inc. Methods of treating coronavirus infection
KR20230003178A (ko) * 2020-04-29 2023-01-05 치아타이 티안큉 파마수티컬 그룹 주식회사 PD-1 및 TGF-β에 대한 이중 기능성 단백질
CA3181949A1 (en) * 2020-05-05 2021-11-11 Janssen Biotech, Inc. Methods of treating crohn's disease with anti-il23 specific antibody
KR20230010251A (ko) 2020-05-13 2023-01-18 보넘 테라퓨틱스, 인크. 단백질 복합체의 조성물 및 그의 사용 방법
CA3183927A1 (en) 2020-05-21 2021-11-25 Janssen Biotech, Inc. Method of treating inflammatory bowel disease with a combination therapy of antibodies to il-23 and tnf alpha
CA3183673A1 (en) * 2020-06-26 2021-12-30 Robert Allen Oncolytic herpes simplex viruses (hsv) expressing immunomodulatory fusion proteins
AU2021308574A1 (en) * 2020-07-13 2023-03-09 Janssen Biotech, Inc. Safe and effective method of treating psoriatic arthritis with anti-IL23 specific antibody
WO2022037606A1 (en) * 2020-08-19 2022-02-24 Bio-Thera Solutions, Ltd. Liquid formulations comprising high concentrations humanized antibodies for treating il-6 related diseases
CA3196496A1 (en) 2020-10-23 2022-04-28 Laurence David TOMS Lag-3 antagonist therapy for lung cancer
CN116897165A (zh) * 2021-02-27 2023-10-17 典晶生物医药科技(苏州)有限公司 靶向il-6受体和血管生成因子的抗体融合蛋白
EP4305062A1 (en) * 2021-03-12 2024-01-17 Janssen Biotech, Inc. Method of treating psoriatic arthritis patients with inadequate response to tnf therapy with anti-il23 specific antibody
BR112023018353A2 (pt) * 2021-03-12 2024-02-06 Janssen Biotech Inc Método seguro e eficaz para tratamento da artrite psoriática com anticorpo específico anti-il23
JP7767613B2 (ja) 2021-11-15 2025-11-11 システィミューン,インコーポレイテッド 二重特異性抗体-カンプトテシン薬物複合体及びその製薬的使用
WO2023146654A1 (en) * 2022-01-31 2023-08-03 Fbd Biologics Limited Engineered pd-1 variants and methods of use thereof
EP4249510A1 (en) * 2022-03-22 2023-09-27 Stealth IO Novel formats of anti-cd28/spd-1 fusion constructs
WO2026085300A1 (en) * 2024-10-16 2026-04-23 Flagship Pioneering Innovations Vii, Llc Compositions and methods

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014164427A1 (en) * 2013-03-12 2014-10-09 Biocon Ltd. Fusion immunomodulatory proteins and methods for making same
US20160168260A1 (en) * 2012-04-30 2016-06-16 Biocon Limited Targeted/immunomodulatory fusion proteins and methods for making same
US20160340430A1 (en) * 2010-03-05 2016-11-24 The Johns Hopkins University Compositions and methods for targeted immunomodulatory antibodies and fusion proteins

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4244946A (en) 1979-06-11 1981-01-13 The Salk Institute For Biological Studies Water-soluble peptides affecting gonadal function
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
US7060808B1 (en) 1995-06-07 2006-06-13 Imclone Systems Incorporated Humanized anti-EGF receptor monoclonal antibody
US5736167A (en) 1997-02-27 1998-04-07 Chang; Hui Hwa Mold device for making safety shoe
WO2005030798A2 (en) * 2003-09-24 2005-04-07 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services TNFαCONVERTING ENZYME INHIBITORY AGENTS AND STIMULATORY AGENTS-
BR112015007672A2 (pt) * 2012-10-04 2017-08-08 Dana Farber Cancer Inst Inc anticorpos anti-pd-l1 monoclonais humanos e métodos de uso
EP3177640B1 (en) * 2014-08-08 2020-05-06 The Board of Trustees of the Leland Stanford Junior University High affinity pd-1 agents and methods of use
WO2016166139A1 (en) * 2015-04-14 2016-10-20 Eberhard Karls Universität Tübingen Bispecific fusion proteins for enhancing immune responses of lymphocytes against tumor cells
WO2021007428A2 (en) * 2019-07-09 2021-01-14 The Johns Hopkins University Molecules, compositions and methods for treatment of cancer

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160340430A1 (en) * 2010-03-05 2016-11-24 The Johns Hopkins University Compositions and methods for targeted immunomodulatory antibodies and fusion proteins
US20160168260A1 (en) * 2012-04-30 2016-06-16 Biocon Limited Targeted/immunomodulatory fusion proteins and methods for making same
WO2014164427A1 (en) * 2013-03-12 2014-10-09 Biocon Ltd. Fusion immunomodulatory proteins and methods for making same

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022111476A1 (zh) * 2020-11-24 2022-06-02 普米斯生物技术(珠海)有限公司 抗PD-L1-抗VEGF-抗TGF-β多特异性抗体、其药物组合物及用途
WO2022111576A1 (en) * 2020-11-27 2022-06-02 Elpiscience (Suzhou) Biopharma, Ltd. Novel conjugate molecules targeting cd39 and tgfβeta
CN115052894A (zh) * 2020-11-27 2022-09-13 科望(苏州)生物医药科技有限公司 靶向cd39和tgfbeta的新型缀合物分子
CN113698493A (zh) * 2021-08-09 2021-11-26 北京东方百泰生物科技股份有限公司 一种针对VEGF和TGF-β的双功能蛋白及其应用
CN113698493B (zh) * 2021-08-09 2022-05-31 北京东方百泰生物科技股份有限公司 一种针对VEGF和TGF-β的双功能蛋白及其应用
WO2024046394A1 (zh) * 2022-08-30 2024-03-07 北京卡替医疗技术有限公司 增强受体、表达增强受体的免疫细胞及其用途
CN116554300A (zh) * 2023-04-27 2023-08-08 湖北医药学院 一种能与艰难拟梭菌毒素TcdB相互作用的多肽及其应用
CN116554300B (zh) * 2023-04-27 2023-10-24 湖北医药学院 一种能与艰难拟梭菌毒素TcdB相互作用的多肽及其应用
WO2026119062A1 (zh) * 2024-12-04 2026-06-11 科辉智药(深圳)新药研究中心有限公司 一种抗pd-l1和hhla2双特异性抗体及其制备方法和应用

Also Published As

Publication number Publication date
US20240158496A1 (en) 2024-05-16
EP4509132A2 (en) 2025-02-19
EP4509132A3 (en) 2025-11-19
EP3630148A1 (en) 2020-04-08
JP2020521759A (ja) 2020-07-27
IL270901A (en) 2020-01-30
US20240400683A1 (en) 2024-12-05
US20200140547A1 (en) 2020-05-07
EP3630148A4 (en) 2021-06-16
WO2018218215A1 (en) 2018-11-29
IL311124A (en) 2024-04-01
CA3064869A1 (en) 2018-11-29

Similar Documents

Publication Publication Date Title
US20240158496A1 (en) Multifunctional btla extracellular domain co-inhibitory moiety traps to modulate immune tolerance
US20220204628A1 (en) Compositions and methods for targeted immunomodulatory antibodies and fusion proteins
JP2020521759A5 (cg-RX-API-DMAC7.html)
US20230365699A1 (en) Antibodies and chimeric antigen receptors specific for b-cell maturation antigen
JP2021522801A (ja) ヒトネクチン4に特異的な抗体
US20260116971A1 (en) Antibodies specific to human nectin-2
WO2022148410A1 (zh) 抗pd-l1/抗4-1bb天然抗体结构样异源二聚体形式双特异抗体及其制备
HK40051189A (en) Compositions and methods for targeted immunomodulatory antibodies and fusion proteins
EA046081B1 (ru) Мультиспецифические связывающие белки и их усовершенствования

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20200717

WD01 Invention patent application deemed withdrawn after publication